Joerg Vollmer, PhD

Joerg Vollmer, PhD has a long and varied work experience. Joerg began their career in 1998 as a Research Fellow for the Max-Planck Institute of Immunobiology and Epigenetics. In 1999 they joined Coley Pharmaceutical Group as a Vice President Discovery & Development, Senior Director, Director, Associate Director, and Lab Head. In 2008 they became Managing Director and Site Lead for Pfizer Oligonucleotide Therapeutics Unit and Member of the Board for BioRiver-Life Science im Rheinland e.V. In 2011 they became Managing Director and Chief Executive Officer for Nexigen GmbH. In 2016 they became Chairman Technology Advisory Board for Silence Therapeutics plc, Chief Scientific Officer for Rigontec GmbH, and Owner of JV BioScience Consultancy. Most recently, in 2019 they became Chief Scientific Officer for Abalos Therapeutics GmbH.

Joerg Vollmer obtained their PhD in Immunology from the Max-Planck Institute of Immunobiology and Epigenetics in 1998. Prior to this, they had obtained a Diploma in Immunology from the same institute in 1995. Joerg had also completed their studies in Cell Biology, Biochemistry, and Genetics from The University of Freiburg between 1989 and 1994. Joerg's educational journey began at the Deutsch-Franz\u00f6sisches Gymnasium / Lyc\u00e9e Franco-Allemand, which they attended prior to 1988.